Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects

Diabetes Care. 2007 Oct;30(10):2579-82. doi: 10.2337/dc07-0320. Epub 2007 May 11.

Abstract

Objective: The current study was designed to test the acute effects of dietary advanced glycation end products (AGEs) on endothelial function of diabetic and nondiabetic subjects.

Research design and methods: Flow-mediated dilation (FMD) of the brachial artery and serum levels of AGEs, plasminogen activator inhibitor 1 (PAI-1), vascular cell adhesion molecule 1 (VCAM-1), and glucose were assessed before and after a single oral AGE challenge (approximately 1.8 x 10(6) AGE units) in 44 diabetic and 10 nondiabetic subjects.

Results: The diabetic patients had higher baseline levels of serum AGEs (P = 0.020), PAI-1 (NS), and VCAM-1 (P = 0.033) and lower baseline values of FMD compared with nondiabetic subjects (P = 0.032). Ninety minutes after a single oral AGE challenge, serum AGEs and PAI-1 levels increased and FMD decreased significantly in both healthy subjects (AGEs: 7.2 +/- 0.5 to 9.3 +/- 1 units/ml, P = 0.014; PAI-1: 5.4 +/- 0.4 to 6.8 +/- 0.4 ng/ml, P = 0.007; and FMD: 9.9 +/- 0.7 to 7.4 +/- 0.9%, P = 0.019) and diabetic subjects (AGEs: 10.5 +/- 0.7 to 14.2 +/- 1 units/ml, P = 0.020; PAI-1: 6.5 +/- 1 to 10 +/- 2 ng/ml, P = 0.030; and FMD: 5.4 +/- 0.4 to 4.0 +/- 0.3%, P = 0.032). Serum glucose and VCAM-1 levels remained unchanged.

Conclusions: Significant increases in serum AGEs can occur together with altered clinical measures of endothelial function in diabetic and nondiabetic subjects after a single modest AGE-rich beverage. Thus, repeated or chronic exposure to high AGE diets could over time lead to and/or accelerate vascular disease.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Administration, Oral
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / physiopathology
  • Diabetes Mellitus / physiopathology*
  • Diabetic Angiopathies / blood
  • Diabetic Angiopathies / physiopathology
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / physiology*
  • Endothelium, Vascular / physiopathology
  • Glycation End Products, Advanced / administration & dosage
  • Glycation End Products, Advanced / blood
  • Glycation End Products, Advanced / pharmacology*
  • Humans
  • Plasminogen Activator Inhibitor 1 / blood
  • Reference Values

Substances

  • Glycation End Products, Advanced
  • Plasminogen Activator Inhibitor 1